



PuriCore Announces Promising Clinical Results for Vashe® Wound Therapy in Post-Operative Care of Skin Grafts on Burns

Cost-effective biocompatible wound treatment shows potential effectiveness in helping ensure graft take

MALVERN, PENNSYLVANIA, and STAFFORD, UK, November 11, 2009 — PuriCore (LSE: PURI), the life sciences company focused on developing and commercializing proprietary solutions that safely, effectively, and naturally kill infectious pathogens, today announced results of a randomized clinical trial showing the potential effectiveness of its Vashe Wound Therapy in the post-operative care of split-thickness skin grafts for burn injuries. Vashe Wound Therapy is a medical device that produces a biocompatible solution to enhance the clinical management of acute and chronic wounds and has been used successfully and without report of adverse events in more than 100,000 wound treatments. It is a safe, effective, and economical alternative to commonly used wound irrigating solutions that inhibit wound healing.

The clinical trial was conducted by Kevin Foster, MD, MBA, FACS, Co-Director of the Arizona Burn Center at the Maricopa Medical Center in Phoenix, Arizona. Results showed that Vashe Wound Therapy is as effective as the control, 5% Sulfamylon® solution (mafenide acetate, USP), a synthetic antimicrobial agent, in the post-operative care of grafts for burns and potentially provides greater pain control. The average graft take for Vashe Wound Therapy and 5% Sulfamylon was 97.4% and 96%, respectively. Infection rates during the trial were equivalent, and none were attributable to the therapy. Further, the trial showed that Vashe Wound Therapy demonstrated greater than a 50% cost savings compared with 5% Sulfamylon. Dr. Foster presented results of this trial at the Southern Regional Burn Conference on November 7, 2009, in Shreveport, LA.

"Vashe Wound Therapy is an exciting new alternative technology that demonstrates clinical efficacy for post operative skin graft irrigation while offering significant overall cost savings," said Dr. Foster. "This trial also suggests that Vashe has further potential for pain improvement opportunities."

"These clinical results are further evidence that Vashe Wound Therapy is highly effective for wound care, offering an additional boost to the body's own defense and without any cytotoxic effects that can slow the rate of wound healing," said PuriCore CEO Greg Bosch. "With the increasing attention to cost-containment in healthcare, Vashe Wound Therapy offers a new cost-effective alternative to traditional wound irrigants."

About Vashe Wound Therapy

Vashe Wound Therapy is a medical device used for moistening, irrigating, cleaning, and debriding acute and chronic wounds including stage I through IV pressure ulcers, stasis ulcers, diabetic ulcers, post-surgical wounds, first and second degree burns, abrasions, and minor irritations of the skin. Vashe Wound Therapy is biocompatible, non-cytotoxic, and non-mutagenic. Research to date demonstrates that the Vashe Solution provides a safe and effective alternative to cytotoxic products currently used to treat infected wounds and post-operative surgical sites and is an important element in the overall plan of care for effective wound management. It is a cost-effective alternative to traditional wound irrigants and is a non-staining solution.

About PuriCore

[PuriCore](#) (LSE: PURI) is a life sciences company focused on developing and commercializing proprietary green solutions that safely, effectively, and naturally kill infectious pathogens without causing harm to human health or the environment. PuriCore's patented, proprietary technology mimics the human body's production of the natural antimicrobial hypochlorous acid, offering a safe and non-hazardous approach to disinfection and sanitization. The Company's products are used in a broad range of markets that depend upon controlling contamination, including food retail and foodservice, medical device disinfection, and wound care. Hypochlorous acid is proven to be safe, environmentally friendly, and fast acting against a broad range of infectious pathogens, including major public health threats of *C.difficile*, *E.coli*, HIV, Human and Animal Influenza (including H5N1 and H1N1 Influenza), *Legionella*, *MRSA*, *M.tuberculosis*, Norovirus, and *Salmonella*. PuriCore is headquartered in Malvern, Pennsylvania, with offices in Stafford and Clevedon, UK.

To receive additional information on PuriCore, please visit our website at www.puricore.com, which does not form part of this press release.

Vashe and PuriCore are registered trademarks of PuriCore Inc. All other trademarks are property of their respective owners.

Contacts

Jennifer Guinan
Sage Strategic Marketing
610.410.8111
jennifer@sagestrat.com

David Correale, VP, Marketing & Strategic Business Development
Sam Johnson, Senior Marketing Manager
PuriCore
484.321.2700 or 866.918.2743